Pantoea calida bacteremia in an adult with end-stage stomach cancer under inpatient care.
Pantoea calida is a gram-negative bacillus that was first identified in 2010. Here, we describe the first known case of P. calida bacteremia in a 77-year-old woman with end-stage stomach cancer under inpatient care. The patient was admitted to our hospital for pain after receiving anti-cancer therapy at outpatient facility. Thirteen days after admission, her temperature rose to 39.6 °C. A blood culture was ordered for suspected bacterial infection, and the patient was treated empirically with ampicillin/sulbactam. Cultures showed white pitting colonies later identified as a Pantoea sp. by biochemical analysis. The isolate's 16S rRNA sequence was identical to that of P. calida (100%), and showed 99.1% similarity with that of Pantoea gaviniae. Matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS) confirmed the species as P. calida with an average spectral score >2.0. The primary isolate was ampicillin-resistant, but susceptible to other antibiotics and the bacteremia was cleared after three days of antibiotic therapy. Since P. calida infection is relatively rare, limited information exists on the pathogen's portal of entry and bacterial characteristics; thus, further studies are necessary to establish the pathophysiological mechanisms P. calida infection.
Department of Clinical Laboratory, Tokyo Metropolitan Health and Medical Treatment Corporation Toshima Hospital, Tokyo, Japan. Electronic address: kageto_yamada@tokyo-hmt.jp.
Kageto
K
Yamada
Department of Clinical Laboratory, Tokyo Metropolitan Health and Medical Treatment Corporation Toshima Hospital, Tokyo, Japan.
Machiko
M
Kashiwa
Department of Clinical Laboratory, Tokyo Metropolitan Health and Medical Treatment Corporation Toshima Hospital, Tokyo, Japan.
Katsumi
K
Arai
Department of Clinical Laboratory, Nihon University Itabashi Hospital, Tokyo, Japan.
Kazuya
K
Satoyoshi
Department of Clinical Laboratory, Nihon University Itabashi Hospital, Tokyo, Japan.
Hiroyuki
H
Nishiyama
D000368:Aged; D000667:Ampicillin / Q000494:pharmacology / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D016470:Bacteremia / Q000150:complications / Q000175:diagnosis / Q000382:microbiology; D004756:Enterobacteriaceae Infections / Q000150:complications / Q000175:diagnosis / Q000382:microbiology; D005260:Female; D006760:Hospitalization; D006801:Humans; D008826:Microbial Sensitivity Tests; D020636:Pantoea / Q000737:chemistry / Q000187:drug effects / Q000302:isolation & purification; D013274:Stomach Neoplasms / Q000150:complications*; D013407:Sulbactam / Q000494:pharmacology / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; C035444:sultamicillin; D000667:Ampicillin; D013407:Sulbactam
Bacteremia; Cancer; Pantoea calida